- Home
- IEX vs INCY Comparison
IEX vs INCY Comparison
Compare IEX & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEX
- INCY
- Stock Information
- Founded
- IEX 1987
- INCY 1991
- Country
- IEX United States
- INCY United States
- Employees
- IEX N/A
- INCY N/A
- Industry
- IEX Fluid Controls
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- IEX Industrials
- INCY Health Care
- Exchange
- IEX Nasdaq
- INCY Nasdaq
- Market Cap
- IEX 13.6B
- INCY 13.0B
- IPO Year
- IEX 1991
- INCY 1993
- Fundamental
- Price
- IEX $158.31
- INCY $78.39
- Analyst Decision
- IEX Buy
- INCY Buy
- Analyst Count
- IEX 8
- INCY 20
- Target Price
- IEX $211.86
- INCY $79.06
- AVG Volume (30 Days)
- IEX 836.7K
- INCY 1.7M
- Earning Date
- IEX 07-30-2025
- INCY 07-29-2025
- Dividend Yield
- IEX 1.79%
- INCY N/A
- EPS Growth
- IEX N/A
- INCY 900.04
- EPS
- IEX 6.18
- INCY 4.37
- Revenue
- IEX $3,340,800,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- IEX $5.97
- INCY $13.53
- Revenue Next Year
- IEX $4.04
- INCY $10.38
- P/E Ratio
- IEX $25.61
- INCY $17.94
- Revenue Growth
- IEX 4.73
- INCY 18.87
- 52 Week Low
- IEX $153.36
- INCY $53.56
- 52 Week High
- IEX $238.22
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- IEX 28.97
- INCY 68.30
- Support Level
- IEX $157.46
- INCY $76.45
- Resistance Level
- IEX $163.01
- INCY $79.43
- Average True Range (ATR)
- IEX 4.20
- INCY 2.16
- MACD
- IEX -2.27
- INCY 0.54
- Stochastic Oscillator
- IEX 2.89
- INCY 91.50
About IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2024.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.